KCNH1 CRISPR/Cas9 KO Plasmid (h): sc-405756
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- KCNH1 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the KCNH1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: KCNH1 Antibody (C-11): sc-398585
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
KCNH1 CRISPR/Cas9 KO Plasmid (h) | sc-405756 | 20 µg | $397.00 |
Overview
KCNH1 encodes a voltage-gated potassium channel (Kv10.1/Eag1) that regulates membrane potential and potassium flux, shaping cellular excitability and downstream calcium-dependent signaling. Beyond electrical properties, KCNH1 activity influences cell-cycle progression, proliferation, and cytoskeletal dynamics through bioelectric control mechanisms and phosphorylation-dependent channel modulation. Expression of KCNH1 has been reported across neural and non-neural contexts, linking channel activity to processes such as neuronal firing patterns and stimulus-dependent signaling. Dysregulation of KCNH1 is associated with neurodevelopmental phenotypes and has been studied in the context of aberrant growth signaling in cancer biology, supporting its use in mechanistic studies of ion channel–driven pathways.
KCNH1 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the KCNH1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the KCNH1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the KCNH1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish KCNH1 protein expression.
This CRISPR knockout system enables efficient generation of KCNH1-deficient cell models for investigation of KCNH1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting KCNH1 exon(s) critical for KCNH1 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple KCNH1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by KCNH1 CRISPR/Cas9 KO Plasmid (h) and KCNH1 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the KCNH1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by KCNH1 HDR Plasmid (h) and KCNH1 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by KCNH1 homology arms to support homology-directed repair at defined KCNH1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.